Business Insights
Diagnostic Technologies
Diseases
Point-of-Care Testing
Research & Development
Sign In
Autoimmune
Cancer
Cardiovascular
COVID-19
Health Topics
Infectious
Skin Cancer
Castle Biosciences shares melanoma test study data at SSO 2024
By
LabPulse.com staff writers
Castle Biosciences shared data from two studies on the performance of its DecisionDx-Melanoma test in patients with cutaneous melanoma at the Society of Surgical Oncology 2024 (SSO 2024) annual meeting, held March 20-23 in Atlanta.
March 26, 2024
FDA grants accelerated approval to Iovance’s melanoma cell therapy
By
LabPulse.com staff writers
The FDA granted accelerated approval to Iovance Biotherapeutics’ T-cell therapy treatment for unresectable or metastatic melanoma.
February 21, 2024
DermTech to lay off 30 employees, take further restructuring measures
By
LabPulse.com staff writers
DermTech will lay off 30 employees and take additional restructuring measures to cut operating expenses, streamline operations, and focus its resources on revenue growth.
February 1, 2024
Cell-penetrating peptide selectively kills melanoma cells in study
By
Matt Limb
Scientists have voiced fresh hopes for metastatic skin cancer therapy after identifying a way to kill melanoma cells efficiently and selectively while sparing normal cells, according to a recent study.
September 8, 2023
Castle Biosciences reports study validation for melanoma gene expression test
By
Maryam Payne
The study findings support results from a recently published study which showed that patients who received routine imaging guided by high-risk 31-GEP test scores had earlier diagnoses of recurrence, which in turn led to better outcomes for patients.
July 6, 2023
DermTech moves to lay off 40 people, focuses on melanoma test to reduce spending
By
Nick Paul Taylor
DermTech is reducing its workforce by 15% as part of a restructuring that will see the company suspend pipeline programs and focus on growing sales of its DMT melanoma test.
June 30, 2023
FDA clears DeepX Diagnostics digital dermatoscope to screen for suspected skin cancer lesions
By
LabPulse.com staff writers
The device has conducted more than 180 thousand assessments in pharmacies and primary care clinics in Europe; DeepX is poised to enter the U.S. market.
June 6, 2023
SkylineDx, NeraCare partner on melanoma test development
By
LabPulse.com staff writers
They entered a co-development and licensing agreement for NeraCare’s proteomic test Immunoprint, which identifies patients with early-stage melanoma who are at high risk of progression, relapse, and death.
April 21, 2023
DermTech obtains melanoma testing coverage for additional 1.9 million people
By
LabPulse.com staff writers
The skin-based genomics test is a noninvasive way to enhance melanoma detection with a greater than 99% negative predictive value, DermTech said.
March 7, 2023
DermTech, Sonora Quest ink deal to broaden access to melanoma detection test
By
LabPulse.com staff writers
Under the agreement, Sonora Quest becomes the exclusive laboratory provider in Arizona for DermTech’s melanoma test.
November 16, 2022
Castle Biosciences reports results for gene expression tests in melanoma study
By
LabPulse.com staff writers
Castle Biosciences described studies evaluating its DecisionDx-Melanoma and DecisionDx-UM gene expression profile tests, conducted in collaboration with the National Cancer Institute.
October 27, 2022
Biocept expands commercial availability of CSF assay to metastatic melanoma
By
LabPulse.com staff writers
The new CNSide for melanoma assay uses an antibody cocktail optimized for the capture of melanoma cells based on unique cellular characteristics.
October 17, 2022
Page 1 of 2
Next Page
